Enhanced bioavailability of process-induced fast-dissolving ibuprofen cogranulated with β-cyclodextrin

Journal of Pharmaceutical Sciences

Volumn 92, Issue 8, 2003, Pages 1690-1697

  Ghorab, Mohamed K ^a,b   Adeyeye, Moji Christianah ^a  

^a DUQUESNE UNIVERSITY   (United States)

^b WYETH RESEARCH   (United States)

Author keywords

Co granulation; Enhanced bioavailability; Fast dissolving; Ibuprofen; cyclodextrin

Indexed keywords

BETA CYCLODEXTRIN; IBUPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BILE DUCT LIGATION; BIOAVAILABILITY; CONTROLLED STUDY; DISSOLUTION; DOSE TIME EFFECT RELATION; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG GRANULE; DRUG SOLUBILITY; DRUG SOLUTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; NONHUMAN; RAT;

EID: 0043211944     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.10443     Document Type: Article

References (25)

1. El-Zein H, Riad L, El-Bary AA. 1998. Enhancement of carbamazepine dissolution: In vitro and in vivo evaluation. Int J Pharm 168(2):209-220.
2. Miyake K, Arima H, Hidetoshi H, Hiryama F, Yamamoto M, Horikawa T, Sumiyoshi H, Noda S, Uekama K. 2000. Improvement of solubility and oral bioavailability of rutin by complexation with 2-hydroxypropyl-β-cyclodextrin. Pharm Dev Technol 5(3):399-407.
3. Badawy SIF, Ghorab MM, Adeyeye CM. 1996. Characterization and bioavailability of danazolhydroxypropyl-β-cyclodextrin coprecipitates. Int J Pharm 128:45-54.
4. Savolainen J, Jarvinen K, Matilainen L, Jarvinen T. 1998. Improved dissolution and bioavailability of phenytoin by sulfobutylether-β-cyclodextrin ((SBE)7m-β-CD) and hydroxypropyl-β-cyclodextrin (HP-β-CD) complexation. Int J Pharm 165(1): 69-78.
5. Backensfeld T, Muller BW, Kolter K. 1991. Interaction of NSA with cyclodextrins and hydroxypropyl cyclodextrin derivatives. Int J Pharm 74:85-93.
6. Krishnamoorthy R, Mitra AK. 1996. Complexation of weak acids and bases with cyclodextrins: Effects of substrate ionization on the estimation and interpretation of association constants. Int J Pharm Adv 1:329-343.
7. Irie T, Uekama K. 1997. Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation. J Pharm Sci 86(2):147-162.
8. Gerloczy A, Fonagy A, Keresztes P, Perlaky L, Szejtli J. 1985. Absorption, distribution, excretion and metabolism of orally administered 14C-beta-cyclodextrin in rat. Arzneim-Forsch 35(7):1042-1047.
9. Habon I, Fritsch S, Szejtli J. 1984. Simulation of pharmacokinetic behavior of drug-cyclodextrin complexes. Pharmazie 39:830-834.
10. Thompson DO. 1997. Cyclodextrins-enabling excipients: Their present and future use in pharmaceuticals. Crit Rev Drug Carrier Syst 14:1-104.
11. Stella VJ, Rajewski RA. 1997. Cyclodextrins: Their future in drug formulation and delivery. Pharm Res 14:556-567.
12. Stella VJ, Venkatramana MR, Zannou EA, Zia V. 1999. Mechanisms of drug release from cyclodextrin complexes. Adv Drug Deliv Rev 36:3-16.
13. Weisbrodt NW. 2000. Bile production, secretion, and storage. In: Johnson LR, editor. Gastrointestinal physiology. New York: Raven Press, pp 107-138.
14. Attwood D, London ATF. 1983. Surfactant systems: Their chemistry, pharmacy, and biology. London: Chapman and Hall, p 794.
15. Tan ZJ, Zhu XX, Brown GR. 1994. Formation of inclusion complexes of cyclodextrins with bile salt anions as determined by NMR titration studies. Langmuir 10:1034-1039.
16. Luner PE, Babu SR, Radebaugh GW. 1994. The effects of bile salts and lipids on the physicochemical behavior of gemfibrozil. Pharm Res 11(12): 1755-1760.
17. Tan X, Lindenbaum S. 1991. Studies on complexation between β-cyclodextrin and bile salts. Int J Pharm 74:127-135.
18. Vandelli MA, Salvioli G, Mucci A, Panini R, Malmusi L, Forni F. 1995. 2-Hydroxypropyl-β-cyclodextrn complexation with ursodeoxycholic acid. Int J Pharm 118:77-83.
19. Frijlink HW, Eissens AC, Schoonen AJM, Lerk CF. 1990. The effects of cyclodextrins on drug absorption. II. In-vivo observations. Int J Pharm 64:195-205.
20. Muller BW, Albers E. 1991. Effect of hydrotropic substances on the complexation of sparingly soluble drugs with cyclodextrin derivatives and the influence of cyclodextrin complexation on the pharmacokinetics of the drugs. J Pharm Sci 80(6):599-604.
21. Nakanishi K, Masada M, Nadai T, Miyajima K. 1989. Effect of the interaction of drug-β-cyclodextrin complex with bile salts on the drug absorption from rat small intestinal lumen. Chem Pharm Bull 37(1):211-214.
22. Ghorab MK, Adeyeye MC. 2001. Enhancement of ibuprofen dissolution via wet granulation with β-cyclodextrin. Pharm Dev Technol 6(3):305-314.
23. 1H-NMR studies. Pharm Dev Technol 6(3): 315-324.
24. Kedzierewicz F, Zinutti C, Hoffman M, Maincent P. 1993. Bioavailability study of tolbutamide β-cyclodextrin inclusion compounds, solid dispersions and bulk powder. Int J Pharm 94(1-3):69-74.
25. El-Gindy GA, Abdel-Mageed A, Hassan MA. 1999. Study of the interaction and hydrolysis of furosemide with cyclodextrins in solution and in the solid states. Bull Pharmaceut Sci 22(2):179-189.